Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Payables (2019 - 2025)

Immunocore Holdings' Payables history spans 4 years, with the latest figure at $24.4 million for Q4 2025.

  • For Q4 2025, Payables fell 2.93% year-over-year to $24.4 million; the TTM value through Dec 2025 reached $24.4 million, down 2.93%, while the annual FY2025 figure was $24.4 million, 2.93% down from the prior year.
  • Payables for Q4 2025 was $24.4 million at Immunocore Holdings, up from $23.0 million in the prior quarter.
  • Across five years, Payables topped out at $67.9 million in Q3 2024 and bottomed at $14.4 million in Q4 2022.
  • The 4-year median for Payables is $23.4 million (2025), against an average of $26.1 million.
  • The largest YoY upside for Payables was 87.76% in 2025 against a maximum downside of 66.21% in 2025.
  • A 4-year view of Payables shows it stood at $14.4 million in 2022, then rose by 23.17% to $17.8 million in 2023, then skyrocketed by 41.03% to $25.1 million in 2024, then fell by 2.93% to $24.4 million in 2025.
  • Per Business Quant, the three most recent readings for IMCR's Payables are $24.4 million (Q4 2025), $23.0 million (Q3 2025), and $23.9 million (Q2 2025).